Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Interstitial Lung Disease (ILD) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Lung Tissue Research Consortium

NCT02988388
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions
Lung biopsy/lobectomy
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 14, 2026, 10:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 765423, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
6
States / cities
Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Platform Clinical Study for Conquering Scleroderma

NCT06195072
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

NCT03824392
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT05185089
View directory record Official record
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

NCT02858791
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

NCT00468208
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Abatacept
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 14, 2026, 10:45 PM EDT
Withdrawn Phase 2 Interventional

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT02603068
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01366209
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Newport Beach, California • Palm Springs, California • Redding, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01254409
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151, Placebo
Biological · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 14, 2026, 10:45 PM EDT
Completed No phase listed Observational

Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis

NCT02735746
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Mediastinum Lesion, Radiation Pneumonitis
Interventions
4D Computed Tomography (CT), Cone Beam CT, Low-dose Cinefluorography, Pulmonary Function Tests
Radiation · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT03832946
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
GB0139, Placebo
Drug
Lead sponsor
Galecto Biotech AB
Industry
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Palm Springs, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Mirdametinib in Histiocytic Disorders

NCT06153173
View directory record Official record
Conditions
Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
Interventions
Mirdametinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

NCT04930289
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions
LungGuard, BAROGuard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Not applicable Interventional

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

NCT03324503
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Glucocorticoid (prednisone or prednisolone)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327
View directory record Official record
Conditions
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

NCT01629667
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Tralokinumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
50 Years to 79 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • La Jolla, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

NCT04079179
View directory record Official record
Conditions
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
Interventions
Cobimetinib
Drug
Lead sponsor
Carl Allen
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Completed No phase listed Observational Results available

Autologous Stem Cell Treatment for Chronic Lung Disease Study

NCT03044431
View directory record Official record
Conditions
COPD, Interstitial Lung Disease
Interventions
Cell therapy
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Study of Artesunate Patients With IPF

NCT05988463
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Artesuante, Placebo capsules
Drug · Other
Lead sponsor
Joseph C. Wu
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 10:45 PM EDT